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(26 patients). The study protocol was approved 
by the university ethics committee. Participants 
provided written informed consent.
All laboratory tests were performed prior to 
randomization of patients to the n‑3 polyunsat‑
urated fatty acids (n‑3 PUFAs) or placebo arm. 
Standard assay techniques were used in routine 
laboratory investigations. Glycated hemoglobin 
(HbA1C) was estimated using turbidimetric in‑
hibition immunoassay. High‑sensitivity C‑re‑
active protein was measured by latex nephe‑
lometry (Dade Behring, Marburg, Germany). 
The serum levels of tumor necrosis factor α and 
interleukin 6 were evaluated by enzyme‑linked 
immunosorbent assays (ELISA; R&D Systems, 
Minneapolis, Minnesota, United States).
Leptin and adiponectin levels were measured 
by radioimmunoassay kits (DIAsource, Louvain‑
la‑Neuve, Belgium). Insulin levels were assessed 
using the chemiluminescent immunoassay meth‑
od (Advia Centaur, Siemens Healthcare, Camber‑
ley, Surrey, United Kingdom). The measurement 
of circulating peptide C was performed using ra‑
dioimmunoassay kits (DIAsource). The concen‑
tration of oxLDL was measured by ELISA (Im‑
mundiagnostik AG, Bensheim, Germany).
Serum phospholipid fatty acids were evalu‑
ated with gas chromatography (Agilent Tech‑
nologies 6890N Network GC Systems, Wilm‑
ington, Delaware, United States). SCD1 activity 
was estimated as the ratios of POA to palmitic 
Introduction There is a  growing body 
of evidence that cis ‑palmitoleic acid (POA, 
cis ‑C16:1n‑7), a n‑7 monounsaturated fatty acid 
(MUFA) mainly produced by desaturation of pal‑
mitic acid via stearoyl ‑CoA desaturase‑1 (SCD1; 
KEGG database, EC 1.14.99.5) can act as a li‑
pokine and influences systemic metabolism.1‑5 
Numerous experimental studies have shown 
the beneficial effects of POA on the mechanisms 
underlying type 2 diabetes (T2D) and atheroscle‑
rotic cardiovascular disease (ASCVD).1,2,5 How‑
ever, data from clinical studies are not conclu‑
sive.1,2,5,6 Little is known about the role of POA 
in the pathogenesis of T2D complications, in‑
cluding diabetic macroangiopathy.
The aim of this study was to assess the associ‑
ation of POA concentration in serum phospho‑
lipids with diabetes duration, systemic inflam‑
mation, and circulating oxidized low ‑density 
lipoprotein (oxLDL) in patients with T2D and 
chronic coronary syndrome (CCS) and angio‑
graphically proven ASCVD.
Methods The study design is described in de‑
tail elsewhere.7 Briefly, 74 patients, including 
26 women (35.1%), with a mean (SD) age of 65.6 
(6.8) years, with T2D (median diabetes duration 
10 years) and CCS were prospectively enrolled in 
the study. All subjects had angiographically doc‑
umented ASCVD, defined as coronary artery dis‑

















S H O R T  C O M M U N I C A T I O N
Serum phospholipid cis ‑palmitoleic acid 
in patients with type 2 diabetes and chronic 
coronary syndrome
An assessment of the relationship with diabetes duration, systemic low ‑grade 
inflammation, and circulating oxidized low ‑density lipoprotein




S H O R T  C O M M U N I C A T I O N  cis ‑Palmitoleic acid in type 2 diabetes and chronic coronary syndrome 585
between serum phospholipid POA and biomark‑
ers of systemic inflammation.
Experimental and clinical studies showed that 
MUFAs have multiple beneficial effects on car‑
diovascular health and glucose homeostasis.6 Al‑
though the POA content in the average Western 
diet is low or very low, POA is the second most 
widespread MUFA, after oleic acid, in fatty tis‑
sue and serum phospholipids.1‑5 It has been shown 
that the content of POA in serum phospholipids 
depends mainly on the hepatic activity of SCD1.5 
Furthermore, the cis ‑C16:1n‑7 to C16:0 index (POA 
to palmitic acid ratio) has been shown to better 
reflect the liver SCD1 activity than the C18:1n‑9 
to C18:0 index (oleic acid to stearic acid ratio).4
Our study showed an inverse relationship be‑
tween serum phospholipid POA and circulating 
oxLDL. This finding is novel and may have im‑
portant implications for understanding the ben‑
eficial effects of n‑7 MUFAs in patients with 
T2D. There is convincing evidence that oxLDL, 
a strong natural prooxidant derived from na‑
tive LDL through cellular oxidation, is an ear‑
ly marker of systemic oxidative stress, involved 
in the pathophysiology of T2D and ASCVD.8,9 
The susceptibility of LDL to oxidation depends 
mainly on the content of unsaturated fatty ac‑
ids, especially PUFAs, and antioxidants.10 Unfor‑
tunately, there have been few nutritional trials 
to date assessing the effect of MUFAs on LDL 
oxidation in patients with T2D, and existing 
ones have compared such intervention only with 
a high ‑carbohydrate diet.10 The results of these 
studies, however, are inconclusive.10
We also found that POA content in serum 
phospholipids of the study patients is inversely 
associated with diabetes duration. The Framing‑
ham Heart Study showed that duration of T2D 
was positively associated with the risk of mor‑
tality associated with coronary artery disease.9 
The relationship between POA concentration 
in serum phospholipids and diabetes duration 
seems to be an interesting finding that could 
be due to alteration to hepatic SCD1 activity in 
patients with T2D, especially those with lon‑
ger history of disease. It has recently been con‑
firmed that in patients with T2D, SCD1 mRNA 
was 5‑fold lower and protein expression 2‑fold 
lower compared with healthy subjects, which 
may lead to altered levels of MUFAs in serum 
phospholipids.11
Although several studies have shown 
the beneficial effects of a MUFA ‑rich diet on 
glycometabolic control and cardiovascular 
risk in patients with T2D, data on MUFA ef‑
fects on systemic inflammation are limited 
and inconclusive.10 Importantly, most stud‑
ies were conducted in experimental models, 
healthy subjects, or individuals with hyper‑
tension, rather than patients with T2D.10 In 
addition, the main dietary MUFA in most of 
the cited studies was oleic acid rather than 
acid (C16:0) and oleic acid (C18:1n‑9) to stearic 
acid (C18:0), as previously described.1‑5 Based 
on the median value of POA, the study partici‑
pants were grouped into those with POA lower 
than 14.9 µmol/l (n = 37) and those with POA 
of 14.9 µmol/l or greater (n = 37).
Statistical analysis Data were presented as 
mean (SD) or median (interquartile range 
[IQR]), as appropriate. Normality was checked 
using the  Shapiro ‑Wilk test. The  t  test or 
the Mann–Whitney test were used to assess 
differences between 2 groups as appropriate. 
Categorical variables were analyzed using the χ2 
test or the Fisher exact test. Correlations were 
calculated with the Spearman rank correlation 
analysis. Stepwise linear regression analysis was 
performed for determining the independent pre‑
dictors of serum phospholipid POA. A 2‑tailed 
P value of less than 0.05 was considered signif‑
icant. Statistical analyses were performed us‑
ing STATISTICA version 13 (Statsoft Inc., Tul‑
sa, Oklahoma, United States).
Results and discussion Individuals with POA 
less than 14.9 µmol/l, compared with patients 
with POA of 14.9 µmol/l or greater had simi‑
lar clinical and demographic characteristics, ex‑
cept for longer diabetes duration (median [IQR], 
11 [8–20] vs 8 [5–10] years; P = 0.01) and lower 
prevalence of obesity (54.1% vs 78.4%; P = 0.03) 
(Supplementary material, Table S1). Patients with 
POA of 14.9 µmol/l or greater had higher levels 
of insulin, C ‑peptide, triglycerides, and estimat‑
ed SCD1 activity (TAblE 1). Moreover, patients with 
higher POA levels had lower plasma concentra‑
tions of oxLDL, adiponectin, and ratio of adipo‑
nectin to leptin (TAblE 1). There were no intergroup 
differences in levels of HbA1c, leptin, total cho‑
lesterol, low ‑density lipoprotein (LDL) cholester‑
ol, high ‑density lipoprotein cholesterol, and sys‑
temic inflammatory markers (interleukin 6, tu‑
mor necrosis factor α, and high‑sensitivity C‑re‑
active protein) (TAblE 1).
Our study showed that POA was inversely 
correlated with diabetes duration (r = –0.29; 
P = 0.02) and circulating oxLDL (r = –0.29; 
P = 0.02) and was positively correlated with es‑
timated SCD1 activity (r = 0.43; P <0.001) (Sup‑
plmentary material, Table S2). Multivariable lin‑
ear regression analysis demonstrated that SCD1 
activity (β = 0.34; 95% CI, 0.13–0.55; P = 0.002), 
LDL cholesterol (β = 0.35; 95% CI 0.14–0.56; 
P = 0.001), and oxLDL (β = –0.22; 95% CI, –0.43 
to –0.02; P = 0.048) were independently associ‑
ated with serum phospholipid POA.
The most important finding of our study is 
that a concentration of POA in serum phospho‑
lipids of patients with T2D and CCS was relat‑
ed to diabetes duration and circulating oxLDL, 
although the associations were of modest mag‑
nitude. No significant relationship was found 
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POA.10 There is growing evidence that indi‑
vidual fatty acids within one class can have 
different effects on systemic inflammation.12 
In our study, no significant association was 
found between serum phospholipid POA and 
inflammatory biomarkers. This finding con‑
firms the complexity of the interaction be‑
tween endogenously synthesized POA, hepat‑
ic SCD1‑mediated Δ9‑desaturation and chron‑
ic low ‑grade inflammation in patients with 
T2D and CCS. Further studies are needed on 
the role of stearoyl ‑CoA desaturase, its iso‑
forms and Δ9‑desaturation products in lipo‑
genic tissues in the pathophysiology of T2D 
and its complications in humans.
Limitations Our study had several limitations. 
First, the cross ‑sectional design of the study did 
not allow us to infer causality. Second, the di‑
etary fat intake including POA was not assessed 
precisely. Finally, the sample size was relative‑
ly small and a larger sample would have provid‑
ed more robust findings.
Table 1  Glycometabolic status, estimated stearoyl ‑CoA desaturase activity, and inflammatory markers in the study patients
Variable Total (n = 74) POA <14.9 µmol/l (n = 37) POA ≥14.9 µmol/l (n = 37) P value
HbA1c, % 7 (6.6–7.5) 7.1 (6.7–7.5) 7 (6.6–7.4) 0.77
Insulin, µIU/ml 21.5 (14.6–33.6) 17.6 (12.1–25.2) 24.5 (17.1–35.3) 0.04
C ‑peptide, ng/ml 3.25 (1.4) 2.89 (1.32) 3.60 (1.41) 0.03
TC, mmol/l 3.86 (0.91) 3.66 (0.76) 4.06 (1.01) 0.06
LDL ‑C, mmol/l 1.91 (1.53–2.64) 1.77 (1.53–2.48) 2.16 (1.61–3.03) 0.11
HDL ‑C, mmol/l 1.24 (0.38) 1.22 (0.37) 1.26 (0.4) 0.75
Tg, mmol/l 1.35 (1.12–1.92) 1.28 (0.96–1.54) 1.65 (1.19–2.47) 0.01
Creatinine, µmol/l 83.7 (22) 85.2 (27.3) 82.2 (15.6) 0.6
eGFR, ml/min/1.73 m2a 78.3 (70–90) 78 (67–90) 86.4 (72–90) 0.31
hsCRP, mg/l 1.54 (0.73–2.71) 1.47 (0.66–1.99) 1.84 (0.82–3.1) 0.23
IL‑6, pg/ml 1.99 (1.55–2.79) 1.82 (1.41–2.5) 2.11 (1.64–3.07) 0.11
TNFα, pg/ml 1.48 (1.28–1.76) 1.48 (1.26–1.82) 1.48 (1.29–1.68) 0.79
oxLDL, ng/ml 58.2 (35.4–128.4) 77.1 (42.1–175.7) 44.3 (28.1–79.8) 0.01
oxLDL to LDL ‑C ratio, µg/mmol 26.9 (18.13–71.9) 47.82 (22.31–115.28) 21.59 (11.31–42.4) 0.01
oxLDL to TC ratio, µg/mmol 14.85 (9.31–36.2) 25.9 (12.08–54.11) 11.58 (6.44–19.46) 0.01
Adiponectin, µg/ml 3.74 (2.85–4.82) 4.07 (3.43–5.84) 3.26 (2.64–4) 0.02
Leptin, ng/ml 3.76 (2.02–8.48) 3.45 (1.81–7.05) 4.8 (2.04–11.04) 0.13
Adiponectin to leptin ratio, µg/ng 0.82 (0.44–2.49) 1.27 (0.55–3.12) 0.59 (0.38–1.51) 0.02
cis ‑C16:1n‑7 to C16:0 index 0.016 (0.013–0.021) 0.014 (0.012–0.015) 0.021 (0.018–0.026) <0.001
C18:1n‑9 to C18:0 index 0.671 (0.588–0.759) 0.626 (0.582–0.712) 0.724 (0.654–0.804) 0.005
Data are presented as median (IQR) or mean (SD).
a Calculated by the abbreviated Modification of Diet in Renal Disease equation
Abbreviations: eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL ‑C, high ‑density lipoprotein cholesterol; hsCRP, high ‑sensitivity C ‑reactive 
protein; IL‑6, interleukin 6; LDL ‑C, low ‑density lipoprotein cholesterol; ox ‑LDL, oxidized low ‑density lipoprotein; POA, cis ‑palmitoleic acid; TC, total cholesterol; 
Tg, triglycerides; TNFα, tumor necrosis factor α
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